Episurf Medical AB (publ) (EPIS-B.ST)
SEK 0.13
(-2.03%)
SEK 0.13
(-2.03%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 2.3 Million SEK | -39.47% |
| 2022 | 3.8 Million SEK | 375.0% |
| 2021 | 800 Thousand SEK | -46.67% |
| 2020 | 1.5 Million SEK | -57.14% |
| 2019 | 3.5 Million SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | -100.0% |
| 2016 | 10.32 Thousand SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| 2009 | - SEK | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 900 Thousand SEK | 0.0% |
| 2024 Q3 | - SEK | 0.0% |
| 2024 Q1 | 1.6 Million SEK | 0.0% |
| 2023 Q4 | 2.3 Million SEK | -32.35% |
| 2023 Q3 | 3.4 Million SEK | -29.17% |
| 2023 Q2 | 4.8 Million SEK | 0.0% |
| 2023 FY | 2.3 Million SEK | -39.47% |
| 2023 Q1 | 4.8 Million SEK | 26.32% |
| 2022 FY | 3.8 Million SEK | 375.0% |
| 2022 Q4 | 3.8 Million SEK | 5.56% |
| 2022 Q3 | 3.6 Million SEK | -12.2% |
| 2022 Q2 | 4.1 Million SEK | -10.87% |
| 2022 Q1 | 4.6 Million SEK | 475.0% |
| 2021 Q1 | 900 Thousand SEK | -40.0% |
| 2021 FY | 800 Thousand SEK | -46.67% |
| 2021 Q3 | 500 Thousand SEK | 0.0% |
| 2021 Q4 | 800 Thousand SEK | 60.0% |
| 2021 Q2 | 500 Thousand SEK | -44.44% |
| 2020 Q3 | 2.1 Million SEK | -19.23% |
| 2020 Q4 | 1.5 Million SEK | -28.57% |
| 2020 FY | 1.5 Million SEK | -57.14% |
| 2020 Q2 | 2.6 Million SEK | -18.75% |
| 2020 Q1 | 3.2 Million SEK | -8.57% |
| 2019 Q1 | 5.1 Million SEK | 0.0% |
| 2019 Q2 | 4.6 Million SEK | -9.8% |
| 2019 Q3 | 4.1 Million SEK | -10.87% |
| 2019 Q4 | 3.5 Million SEK | -14.63% |
| 2019 FY | 3.5 Million SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 FY | - SEK | -100.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q1 | - SEK | -100.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | 10.32 Thousand SEK | 0.0% |
| 2016 FY | 10.32 Thousand SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2013 Q2 | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 Q1 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Acarix AB (publ) | - SEK | -Infinity% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.842% |
| ADDvise Group AB (publ) | 1.45 Billion SEK | 99.842% |
| Arcoma AB | 1.92 Million SEK | -19.357% |
| Bactiguard Holding AB (publ) | 42.3 Million SEK | 94.563% |
| BICO Group AB (publ) | 1.75 Billion SEK | 99.869% |
| Boule Diagnostics AB (publ) | 57.7 Million SEK | 96.014% |
| CellaVision AB (publ) | 28.66 Million SEK | 91.976% |
| Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -931.39% |
| Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
| C-Rad AB (publ) | 1.75 Million SEK | -31.204% |
| Duearity AB (publ) | 2.94 Million SEK | 21.769% |
| Dignitana AB (publ) | 6.07 Million SEK | 62.152% |
| Getinge AB (publ) | 3.9 Billion SEK | 99.941% |
| Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 63.796% |
| Iconovo AB (publ) | 4.9 Million SEK | 53.127% |
| Integrum AB (publ) | 4.84 Million SEK | 52.524% |
| Luxbright AB (publ) | 206.02 Thousand SEK | -1016.375% |
| Mentice AB (publ) | 2.14 Million SEK | -7.276% |
| OssDsign AB (publ) | 214 Thousand SEK | -974.766% |
| Paxman AB (publ) | 2.53 Million SEK | 9.163% |
| Promimic AB (publ) | - SEK | -Infinity% |
| Qlife Holding AB (publ) | 3 Million SEK | 23.435% |
| SciBase Holding AB (publ) | 4.17 Million SEK | 44.963% |
| ScandiDos AB (publ) | - SEK | -Infinity% |
| Sectra AB (publ) | 19.2 Million SEK | 88.023% |
| Sedana Medical AB (publ) | 1.01 Million SEK | -127.273% |
| Senzime AB (publ) | 8.57 Million SEK | 73.187% |
| SpectraCure AB (publ) | 4.39 Million SEK | 47.692% |
| Stille AB | 38.06 Million SEK | 93.958% |
| Vitrolife AB (publ) | 1.87 Billion SEK | 99.877% |
| Xvivo Perfusion AB (publ) | 21.16 Million SEK | 89.135% |